AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors

In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned the abstracts and companies he would be tracking during the upcoming AAIC.

This could include aducanumab by Biogen Inc BIIB and solanezumab by Eli Lilly and Co LLY.

AAIC is scheduled between July 18 and 22. Analyst Mark Schoenebaum noted the planner for abstracts that they would be will be tracking:

Saturday - July 18

• POSTER

Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Exhibit Hall E
IC-P-030
12:15pm - 2:15pm

Tuesday - July 21

• POSTER

Safety of Solanezumab in the Expedition-EXT Study up to 2 Years in a Mild to Moderate Alzheimer's Disease Population
Exhibit Hall D
P3-285
9:30am - 4:15pm

• ORAL

Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Hall E
03-01-04
2:00pm - 3:30pm

Wednesday – July 22

• ORAL

Delayed-Start Analyses of up to 3.5 Years in the Phase 3 Solanezumab Expedition Program in Mild Alzheimer's Disease
Ballroom A
04-03-02
8:00am - 9:30am

• POSTER

Rvt-101, a 5-HT6 Receptor Antagonist, As Adjunctive Therapy with Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Responder Analysis
Exhibit Hall E
P4-302
9:30am - 4:15pm

• ORAL

Aducanumab (BIIB037), an Anti-Amyloid Beta Monoclonal Antibody, in Patients with Prodromal or Mild Alzheimer's Disease: Interim Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1B Study
146
04-04-05
2:00pm - 3:30pm

• ORAL

The Efficacy of Rvt-101, a 5-HT6 Receptor Antagonist, As an Adjunct to Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Completer Analysis of a Phase 2b Study
Hall E
DT-01-04
2:00pm - 3:30pm

• Axovant Investor Briefing

Doors open at 5:15pm
Presentation begins 5:45pm
Marriott Marquis, Georgetown Room, 900 Massachusetts Ave. Northwest, Washington, DC 20001